FDA Approval Accelerates: Top Biotech Stocks to Watch
In 2025, the FDA (U.S. Food and Drug Administration) is clearly accelerating its drug approval process. As of mid-year, over 45 new drugs have been approved, surpassing the total for the same period in 2023. More importantly, many innovative treatments in gene editing, mRNA technology, and rare diseases are receiving “Priority Review” or even “Accelerated Approval.” This has reignited investor interest in biotech stocks.
So, which biotech companies are most worth watching in the second half of 2025?
1. Vertex Pharmaceuticals (VRTX)
- Focus: Gene editing therapy
- Highlight: In collaboration with CRISPR Therapeutics, it launched the first FDA-approved CRISPR-based gene editing therapy, targeting sickle cell disease and beta-thalassemia. The market is highly optimistic, and the treatment is expected to generate over $2 billion in revenue in 2025.
- Why Watch: As the first to commercialize CRISPR therapy, it holds first-mover advantage and technological leadership.
2. Moderna (MRNA)
- Focus: mRNA vaccines and therapeutics
- Highlight: After the COVID-19 vaccine, Moderna is expanding its mRNA platform into RSV, flu, and cancer treatment. The mRNA cancer vaccine in partnership with Merck has entered Phase 3 trials and received FDA Breakthrough Therapy designation.
- Why Watch: mRNA is no longer just for vaccines. Moderna is striving to transform chronic disease treatment through mRNA drugs.
3. Regeneron Pharmaceuticals (REGN)
- Focus: Antibody therapies, ophthalmology, and oncology
- Highlight: The next-generation eye drug Eylea HD has been approved and is expected to further boost the company’s dominance in the macular degeneration market.
- Why Watch: Regeneron maintains strong pipelines in inflammation and cancer, and revenue remains stable with high gross margins.
4. Beam Therapeutics (BEAM)
- Focus: Precision gene editing (base editing)
- Highlight: BEAM-101, based on base editing, is in clinical trials for sickle cell disease and is expected to file for FDA approval in early 2026.
- Why Watch: Base editing is more precise and safer than CRISPR. Beam is one of the few players in this field with high potential and high risk.
5. Sana Biotechnology (SANA)
- Focus: Cell engineering and regenerative medicine
- Highlight: Its allogeneic stem cell therapy platform aims to replace damaged cells in diabetes, Parkinson’s, and cardiac diseases. The pipeline is still early, but partnerships with large pharma companies are strengthening.
- Why Watch: Although still pre-commercial, Sana may achieve breakthroughs in regenerative medicine. Suitable for long-term high-risk investors.
6. Karuna Therapeutics (KRTX)
- Focus: Psychiatric disorders
- Highlight: Its schizophrenia drug KarXT has passed Phase 3 trials and is expected to receive FDA approval in late 2025.
- Why Watch: Mental illness is a vast and long-underserved market. KarXT is the first innovative treatment in years and has blockbuster potential.
7. Ardelyx (ARDX)
- Focus: Kidney and gastrointestinal diseases
- Highlight: Its drug for hyperphosphatemia has been approved, and prescription growth is accelerating. Despite small market cap, it has strong product-market fit.
- Why Watch: Small-cap biotech with real revenue and growing adoption — rare in the market and potentially a hidden gem.
📊 Comparison Table
| Company | Stock Code | Therapeutic Area | 2025 Highlight | Risk Level | Growth Potential |
|---|---|---|---|---|---|
| Vertex | VRTX | Gene editing | First CRISPR therapy launched | Medium | ★★★★★ |
| Moderna | MRNA | mRNA therapeutics | Expanding into RSV, cancer | Medium | ★★★★☆ |
| Regeneron | REGN | Ophthalmology & oncology | Eylea HD approved | Low | ★★★★☆ |
| Beam Therapeutics | BEAM | Base editing | BEAM-101 in trials | High | ★★★★☆ |
| Sana Biotechnology | SANA | Regenerative medicine | Preclinical, strong partnerships | High | ★★★★☆ |
| Karuna Therapeutics | KRTX | Psychiatric drugs | KarXT may receive FDA approval | Medium | ★★★★★ |
| Ardelyx | ARDX | Kidney/GI diseases | Drug sales accelerating | Medium | ★★★★☆ |
Final Thoughts
The biotech sector in 2025 is entering a new phase of growth. With the FDA accelerating its review process and capital flowing back to innovation, some companies are making real breakthroughs — not just concepts. That said, biotech investing always comes with high volatility and requires deep understanding of science and regulatory trends.
If you’re looking for a balance of innovation and commercial potential, Vertex, Regeneron, and Moderna are safer bets. For aggressive investors, Beam, Sana, and Karuna offer asymmetric upside.
👉 If you found this helpful, feel free to share, save, or leave a comment below with your favorite biotech stock for 2025. Let’s discuss.
